Barrier Restoration for Disorders of Gut–Brain Interaction: The Lancet Gastroenterology & Hepatology | July 2026

Introduction:

Disorders of gut–brain interaction (DGBI), including irritable bowel syndrome (IBS) and functional dyspepsia (FD), are increasingly recognised as disorders of impaired intestinal barrier function rather than purely functional diseases. This review explores intestinal barrier restoration as a novel disease-modifying therapeutic strategy.

Why was this article needed?

• Current DGBI treatments primarily target symptoms rather than underlying disease mechanisms.
• Increasing evidence links impaired intestinal barrier integrity with symptom generation.
• Gut barrier dysfunction promotes immune activation, microbial translocation, and abnormal gut–brain signalling.
• Novel therapies targeting epithelial repair are rapidly emerging.
• Personalized treatment strategies based on barrier dysfunction require an updated evidence review.

Key Takeaways:

• Intestinal barrier dysfunction—including disruption of epithelial tight junctions, mucus layer integrity, and increased intestinal permeability—is a central mechanism underlying IBS and functional dyspepsia.
• Short-chain fatty acids, glutamine, tryptophan, dietary fibre, and selected probiotics strengthen epithelial barrier integrity, improve mucin production, and reduce intestinal permeability.
• Psychological stress, Western-style high-fat diets, and low-fibre intake impair barrier function, promoting immune activation, mast cell signaling, microbial translocation, and visceral hypersensitivity.
• Emerging pharmacological therapies—including mast cell stabilizers, antihistamines, protease inhibitors, guanylate cyclase-C agonists, and intestinal secretagogues—may improve symptoms by restoring epithelial barrier function rather than simply suppressing symptoms.
• Novel technologies such as vagus nerve stimulation and barrier-protective hydrogel delivery systems represent promising future therapeutic approaches.
• Future precision medicine in DGBI will likely combine microbial profiling, immune phenotyping, and intestinal permeability assessment to identify patients most likely to benefit from barrier-directed therapies.

Clinical Impact:

This review proposes a paradigm shift in the management of disorders of gut–brain interaction, moving beyond symptomatic treatment toward disease modification through restoration of intestinal barrier integrity. Personalized therapies targeting epithelial dysfunction, microbiota, immune activation, and gut–brain communication may substantially improve long-term outcomes.

Bottom Line:

Restoring intestinal barrier function has emerged as one of the most promising disease-modifying strategies for IBS and other disorders of gut–brain interaction. Combining dietary optimization, microbiome-targeted therapies, stress reduction, and novel barrier-protective pharmacological agents may redefine the future management of these highly prevalent conditions.